Bayer and Janssen Pharmaceuticals are conducting a Phase III Xarelto study, which will include 7,000 patients in 350 sites throughout more than 25 countries. The study aims to determine the effectiveness of the drug in secondary prevention of stroke and embolism — though some patients claim Xarelto is responsible for serious side effects, including stroke.
Xarelto (generic name rivaroxaban) is in a class of drugs known as Xa inhibitors. The drug was originally approved by the U.S. Food and Drug Administration in 2011 to help prevent blood clots in patients who have suffered strokes, atrial fibrillation and other conditions. However, nearly 2,000 patients have reported serious Xarelto side effects, including blood clots.
Bayer and Janssen now face multiple Xarelto lawsuits alleging that the drug caused serious complications in patients. Of the more than 1,800 reports of adverse events, 891 resulted in hospitalization and 183 resulted in deaths.